Takeda Touts Oral Triplet Regimen With Velcade Follow-On MLN9708
This article was originally published in The Pink Sheet Daily
Executive Summary
Results from the FIRST study of long-term treatment with Celgene’s Revlimid/dexamethasone duo were well-received at the ASH meeting. Takeda believes adding on its oral proteasome inhibitor MLN9708 to form a trio could further improve outcomes and is actively evaluating a role for maintenance in pivotal trials, following encouraging Phase I/II results.